AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer

NCT00303862 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: cediranib maleate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)